Antitumor effect and biological pathways of a recombinant adeno-associated virus as a human renal cell carcinoma suppressor

Tumor Biology

Volumn 35, Issue 11, 2014, Pages 10993-11003

  Chen, Jie ^a   Ruan, Xiyun ^b   Wang, Shaomei ^a   Zhang, Bin ^a   Liu, Bo ^c   Sun, Zeqiang ^d   Liu, Qingyong ^d  

^a JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c JINING MEDICAL UNIVERSITY   (China)

^d SHANDONG UNIVERSITY   (China)

Author keywords

Pathway enrichment analysis; Protein protein interaction network; Recombinant adeno associated virus; Renal cell carcinoma; Von Hippel Lindau

Indexed keywords

CAPSID PROTEIN; HYBRID PROTEIN; MESSENGER RNA; TRANSACTIVATOR PROTEIN; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

ANIMAL; APOPTOSIS; CARCINOMA, RENAL CELL; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIS; DEPENDOPARVOVIRUS; DRUG SCREENING; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; KIDNEY NEOPLASMS; METABOLISM; PATHOLOGY; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THERAPEUTIC USE; TUMOR CELL CULTURE; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CAPSID PROTEINS; CARCINOMA, RENAL CELL; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DEPENDOVIRUS; GENE PRODUCTS, TAT; GENETIC THERAPY; GENETIC VECTORS; HUMANS; KIDNEY NEOPLASMS; PROTEIN INTERACTION MAPS; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR BURDEN; TUMOR CELLS, CULTURED; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939896568     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2393-z     Document Type: Article

References (42)

1. Nelson EC, Evans CP, Lara Jr PN. Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev. 2007;33:299–313.
2. Coppin C, Le L, Porzsolt F, Wilt T Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev. 2008;2
3. Van Spronsen D, De Weijer K, Mulders P, De Mulder P. Novel treatment strategies in clear-cell metastatic renal cell carcinoma. Anti-Cancer Drugs. 2005;16:709–17.
4. Fukui N, Kageyama Y, Higashi Y, Kihara K, Kizaka-Kondoh S, Hiraoka M, et al. Development of a novel interferon-α2b gene construct with a repetitive hypoxia-inducible factor binding site and its suppressive effects on human renal cell carcinoma cell lines in vitro. Int J Clin Oncol. 2014;19:497–504.
5. Board RE, Thistlethwaite FC, Hawkins RE. Anti-angiogenic therapy in the treatment of advanced renal cell cancer. Cancer Treat Rev. 2007;33:1–8.
6. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722–31.
7. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev. 2008;21:583–93.
8. Morris MR, Ricketts CJ, Gentle D, McRonald F, Carli N, Khalili H, et al. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene. 2011;30:1390–401.
9. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, et al. Exome sequencing identifies frequent mutation of the swi/snf complex gene pbrm1 in renal carcinoma. Nature. 2011;469:539–42.
10. Thompson M. Polybromo-1: the chromatin targeting subunit of the pbaf complex. Biochimie. 2009;91:309–19.
11. Tang XJ, Ping BH, Pan CE, Yang GX, Wang QY. [Construction and identification of recombinant adeno-associated virus vector harboring fusion gene NT4-Ant-Shepherdin[79-87]]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2008;24:1143–6.
12. Zheng Y, Zeng H, She H, Liu H, Sun N. Expression of peptide nap in rat retinal müller cells prevents hypoxia-induced retinal injuries and promotes retinal neurons growth. Biomed Pharmacother. 2010;64:417–23.
13. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W. The von Hippel–Lindau tumor suppressor protein is a component of an E3 ubiquitin–protein ligase activity. Genes Dev. 1999;13:1822–33.
14. Na X, Duan HO, Messing EM, Schoen SR, Ryan CK, di Sant’Agnese PA, et al. Identification of the rna polymerase II subunit hsRPB7 as a novel target of the von Hippel–Lindau protein. EMBO J. 2003;22:4249–59.
15. Pause A, Lee S, Worrell RA, Chen DY, Burgess WH, Linehan WM, et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci. 1997;94:2156–61.
16. Kim W, Kaelin Jr WG. The von Hippel–Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr Opin Gen Dev. 2003;13:55–60.
17. George DJ, Kaelin WG. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med. 2003;349:419–21.
18. Haase VH. The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting. Semin Cell Dev Biol. 2005;16:564–74.
19. Wizigmann-Voos S, Plate K: Pathology, genetics and cell biology of hemangioblastomas. 1996
20. Kaelin WG. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res. 2004;10:6290S–5.
21. Sambrook J, Russell D. Molecular cloning: a laboratory manual, vol. 1. New York: Cold Spring Harbor Laboratory Press; 2001. 6.4-6.11.
22. Gardner PS, McQuillin J Rapid virus diagnosis: application of immunofluorescence. Butterworth-Heinemann. 1980.
23. Fenwick F, Young B, McGuckin R, Robinson M, Taha Y, Taylor C, et al. Diagnosis of human metapneumovirus by immunofluorescence staining with monoclonal antibodies in the north-east of england. J Clin Virol. 2007;40:193–6.
24. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 1995;184:39–51.
25. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using david bioinformatics resources. Nat Protoc. 2008;4:44–57.
26. Hosack DA, Dennis Jr G, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with ease. Genome Biol. 2003;4:R70.
27. Datta K, Sundberg C, Karumanchi SA, Mukhopadhyay D. The 104–123 amino acid sequence of the β-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. Cancer Res. 2001;61:1768–75.
28. Qin C, Cao Q, Ju X, Wang M, Meng X, Zhu J, et al. The polymorphisms in the VHL and HIF1A genes are associated with the prognosis but not the development of renal cell carcinoma. Ann Oncol. 2012;23:981–9.
29. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1α by the von Hippel-Lindau tumor suppressor protein. EMBO J. 2000;19:4298–309.
30. Ohh M, Park CW, Ivan M, Hoffman MA, Kim T-Y, Huang LE, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the &bgr;-domain of the von Hippel–Lindau protein. Nat Cell Biol. 2000;2:423–7.
31. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW. Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci. 2000;97:10430–5.
32. Groulx I, Bonicalzi M-E, Lee S. Ran-mediated nuclear export of the von Hippel-Lindau tumor suppressor protein occurs independently of its assembly with cullin-2. J Biol Chem. 2000;275:8991–9000.
33. Woodward ER, Clifford SC, Astuti D, Affara NA, Maher ER. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. J Med Genet. 2000;37:348–53.
34. Panchenko MV, Zhou MI, Cohen HT. Von Hippel-Lindau partner Jade-1 is a transcriptional co-activator associated with histone acetyltransferase activity. J Biol Chem. 2004;279:56032–41.
35. Iwai K, Yamanaka K, Kamura T, Minato N, Conaway RC, Conaway JW, et al. Identification of the von Hippel–Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci. 1999;96:12436–41.
36. Clark PE, Cookson MS. The von Hippel-Lindau gene. Cancer. 2008;113:1768–78.
37. Ollerenshaw M, Page T, Hammonds J, Demaine A. Polymorphisms in the hypoxia inducible factor-1alpha gene (HIF1A) are associated with the renal cell carcinoma phenotype. Cancer Genet Cytogenet. 2004;153:122–6.
38. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang G-W, Clifford SC, et al. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem. 2000;275:25733–41.
39. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013;45:860–7.
40. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, et al. Regulation of hypoxia-inducible mrnas by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol. 1998;18:732–41.
41. Knighton D, Ausprunk D, Tapper D, Folkman J. Avascular and vascular phases of tumour growth in the chick embryo. Br J Cancer. 1977;35:347.
42. Tufan AC, Satiroglu-Tufan N. The chick embryo chorioallantoic membrane as a model system for the study of tumor angiogenesis, invasion and development of anti-angiogenic agents. Curr Cancer Drug Targets. 2005;5:249–66.